Archynetys Live news trend intelligence
▲ Peaking Health

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

Takeda's Qdenga has become the first dengue vaccine approved in India, targeting one of the world's most at-risk populations.

7sources
8articles
5velocity
+89%since first seen
10h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

India has approved Qdenga, a vaccine developed by Japanese drugmaker Takeda, as the country's first dengue vaccine. The Central Drugs Standard Control Organisation (DCGI) has cleared the vaccine for individuals between the ages of 4 and 60.

Coverage from Reuters, NDTV, and The Hindu emphasizes the vaccine's eligibility criteria and its role in providing prevention for a high-risk population. The Times of India reports that a city-based private university conducted a chemical trial for the vaccine and notes that immunity remains a challenge due to four different virus strains.

Future developments will likely center on the specific details of effectiveness, dosing, and the rollout for eligible age groups as outlined in reports by NDTV.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.

Quick answers

Who is eligible for the Qdenga vaccine in India?

The vaccine is approved for individuals aged 4 to 60 years.

Which organization approved the vaccine?

The DCGI cleared the vaccine for use in India.

Who developed the vaccine?

The vaccine was developed by the Japanese drugmaker Takeda.

Coverage (8)

Topics

Related trends